Proof of principle of the efficacy of IL-6 receptor blockade in severe systemic juvenile idiopathic arthritis (SJIA)

被引：0
|
作者：
Woo, P
Wilkinson, N
Prieur, A
Southwood, T
Leone, V
Livermore, P
Wythe, H
Thomson, D
Kishimoto, T
机构：
[1] Great Ormond St Hosp Sick Children, Rheumatol Unit, London WC1N 3JH, England
[2] Hop Necker Enfants Malad, Dept Pediat Rheumatol, Paris, France
[3] Birmingham Childrens Hosp NHS Trust, Birmingham, W Midlands, England
[4] Chugai Pharmaceut Co Ltd, London, England
[5] Osaka Univ, Grad Sch Frontier Biosci, Lab Immune Regulat, Osaka, Japan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2005年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [1] Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement
    Woo, P
    Wilkinson, N
    Prieur, AM
    Southwood, T
    Leone, V
    Livermore, P
    Wythe, H
    Thomson, D
    Kishimoto, T
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (06) : R1281 - R1288
  • [2] Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement
    Patricia Woo
    Nicholas Wilkinson
    Anne-Marie Prieur
    Taunton Southwood
    Valentina Leone
    Polly Livermore
    Helena Wythe
    David Thomson
    Tadamitsu Kishimoto
    Arthritis Research & Therapy, 7
  • [3] IL-6 blockers in systemic onset juvenile idiopathic arthritis
    Barone, Patrizia
    Pignataro, Rossana
    Garozzo, Maria Teresa
    Leonardi, Salvatore
    IMMUNOTHERAPY, 2016, 8 (01) : 79 - 87
  • [4] Rapid improvement of signs and symptoms associated with systemic juvenile idiopathic arthritis (sJIA) by interleukin-6 (IL-6) blockade-results from a tocilizumab sJIA phase III clinical trial.
    Yokota, Shumpei
    Imagawa, Tomoyuki
    Mori, Masaaki
    Takei, Syuji
    Yoshifumi, I
    Iwata, Naomi
    Tomiita, Minako
    Miyoshi, Mari
    Aihara, Yuko
    Murata, Takuji
    Abukawa, Daiki
    Nishimoto, Norihiro
    Kishimoto, Tadamitsu
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S327 - S327
  • [5] IL-6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis
    Yokota, S
    Miyamae, T
    Imagawa, T
    Mori, M
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S22 - S23
  • [6] IL-6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis
    S Yokota
    T Miyamae
    T Imagawa
    M Mori
    Arthritis Res Ther, 5
  • [7] In-vitro Influence of TNF-α, IL-1 and IL-6 Antagonists (Biologicals) of the Cytokine Network in Patients with systemic juvenile idiopathic Arthritis (sJIA)
    Robinson, B.
    Kirchner, M.
    Sonnenschein, A.
    Mannhardt-Laakmann, W.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 95 - 95
  • [8] Novel IL-10 gene family associations with systemic juvenile idiopathic arthritis (SJIA)
    Fife, M. S.
    Gutierrez, A.
    Ogilvie, E. M.
    Stock, C. J. W.
    Samuel, J. M.
    Thomson, W.
    Lewis, C.
    Woo, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 287 - 288
  • [9] Reversible Hepatotoxicity to IL-1/IL-6 Blockade in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome
    Phadke, Omkar
    Prahalad, Sampath
    Rouster-Stevens, Kelly
    ARTHRITIS & RHEUMATOLOGY, 2020, 72 : 175 - 176
  • [10] Anti-IL-6 receptor antibody therapy of a girl with severe systemic juvenile idiopathic arthritis.
    Yamazaki, T
    Agematsu, K
    Tanaka, M
    Nagumo, H
    Yasui, K
    Komiyama, A
    CLINICAL IMMUNOLOGY, 2002, 103 (03) : S81 - S81
12345